血清抗-HBC、CHE、载脂蛋白AI的水平与病毒性肝炎发展的相关性  

Correlation between Serum Levels of Anti-HBC,CHE,and Apolipoprotein AI and the Development of Viral Hepatitis

作　　者：徐苏 刘宇晴 郑兴旺 XU Su;LIU Yuqing;ZHENG Xingwang(Clinical Laboratory,Nanjing Pukou District Hospital of Traditional Chinese Medicine,Nanjing Jiangsu 211800;Clinical Laboratory,Affiliated Hospital of Nantong University,Nantong Jiangsu 226001,China)

机构地区：[1]南京市浦口区中医院检验科,江苏南京211800 [2]南通大学附属医院检验科,江苏南通226001

出　　处：《昆明医科大学学报》2024年第12期147-152,共6页Journal of Kunming Medical University

基　　金：浦口区科技计划项目(S2022-27)。

摘　　要：目的探讨血清乙型肝炎病毒核心抗体(hepatitis B core anbody,抗-HBC)、胆碱酯酶(cholinesterase,CHE)、载脂蛋白AI的水平与病毒性肝炎发展的相关性。方法选取南京市浦口区中医院2021年1月至2024年1月收治的388例病毒性肝炎患者作为观察组;另选取同期68例健康体检者作为对照组,比较观察组与对照组血清抗-HBC、CHE、载脂蛋白AI水平。比较观察组中慢性肝炎不同病情严重程度患者血清抗-HBC、CHE、载脂蛋白AI水平。比较观察组中不同疾病类型患者血清抗-HBC、CHE、载脂蛋白AI检测阳性例数。比较观察组中肝硬化不同分级患者血清抗-HBC、CHE、载脂蛋白AI水平。结果观察组血清抗-HBC水平(4.52±0.63)log10PEIU/mL高于对照组(1.12±0.26)log10PEIU/mL,差异有统计学意义(t=-43.822,P<0.001),而CHE(4.09±0.91)kU/L、载脂蛋白AI(102.54±5.95)mg/dL均低于对照组的(10.65±1.73)kU/L、(120.17±6.06)mg/dL,差异有统计学意义(t=46.580、22.477,P<0.001);观察组中慢性肝炎不同病情严重程度患者血清抗-HBC、CHE、载脂蛋白AI水平差异均有统计学意义(P<0.05),且血清抗-HBC水平显示慢性肝炎轻度<慢性肝炎中度<慢性肝炎重度,而CHE、载脂蛋白AI水平显示慢性肝炎轻度>慢性肝炎中度>慢性肝炎重度,差异有统计学意义(P<0.05);慢性肝炎重度、肝硬化及肝癌的血清抗-HBC、CHE、载脂蛋白AI的阳性例数明显高于慢性肝炎轻度、中度,差异有统计学意义(P<0.05);观察组中肝硬化不同分级患者血清抗-HBC、CHE、载脂蛋白AI水平差异有统计学意义(P<0.05),且随病情的发展血清抗-HBC水平不断增高,而CHE、载脂蛋白AI均不断降低,差异有统计学意义(P<0.05)。结论病毒性肝炎患者血清抗-HBC的表达水平显著升高,CHE、载脂蛋白AI的表达水平明显降低,且血清抗-HBC、CHE、载脂蛋白AI的表达水平与其疾病发展相关。Objective To investigate the correlation between serum hepatitis B core anbody(anti-HBC),cholinesterase(CHE)and apolipoprotein AI(ApoAI)and the development of viral hepatitis.Methods 388 patients with viral hepatitis admitted to Nanjing Pukou District Hospital of Traditional Chinese Medicine from January 2021 to January 2024 were selected as the observation group,another 68 cases of health check-ups in medical check-up centre of Nanjing Pukou District Hospital of Traditional Chinese Medicine during the same period were selected as the control group.The serum levels of anti-HBC,CHE,and apolipoprotein AI between the observation group and the control group were compared.To compare the serum anti-HBC,CHE,ApoAI levels in patients with different disease severity of chronic hepatitis in the observation group.To compare the number of positive cases of serum anti-HBC,CHE,ApoAI in patients with different disease types in the observation group.To compare the serum anti-HBC,CHE,ApoAI levels in patients with different grades of cirrhosis in the observation group.Results Serum anti-HBC levels(4.52±0.63)log10PEIU/mL were higher in the observation group than in the control group(1.12±0.26)log10PEIU/mL,and the differences were statistically significant(t=-43.822,P<0.001),while CHE(4.09±0.91)kU/L,ApoAI(102.54±5.95)mg/dL were lower than the control group(10.65±1.73)kU/L,(120.17±6.06)mg/dL,and the differences were statistically significant(t=46.580,22.477,P<0.001);differences in serum anti-HBC,CHE,and ApoAI levels among patients with different severity of chronic hepatitis in the observation group were statistically significant(P<0.05),and the serum levels of anti-HBC levels showed mild chronic hepatitis<moderate chronic hepatitis<severe chronic hepatitis,while the levels of CHE and ApoAI showed mild chronic hepatitis>moderate chronic hepatitis>severe chronic hepatitis the difference was statistically significant(P<0.05);the number of positive cases of serum anti-HBC,CHE,ApoAI in acute jaundiced hepatitis,severe chronic hepati

关 键 词：病毒性肝炎 抗-HBC 胆碱酯酶 载脂蛋白 

分 类 号：R511[医药卫生—内科学]